Clinical Trial Update: Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating hypofractionated stereotactic irradiation with pembrolizumab and bevacizumab for recurrent high-grade gliomas has completed and results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Malignant Glioma | Phase 1 | Status: COMPLETED | Results posted: 2023-10-23